Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jurgen Del-Favero is active.

Publication


Featured researches published by Jurgen Del-Favero.


Nature Genetics | 2011

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease

Yukihide Momozawa; Myriam Mni; Kayo Nakamura; Wouter Coppieters; Sven Almer; Leila Amininejad; Isabelle Cleynen; Jean-Frederic Colombel; Peter De Rijk; Olivier Dewit; Yigael Finkel; Miquel Gassull; Dirk Goossens; Debby Laukens; Marc Lemann; Cécile Libioulle; Colm O'Morain; Catherine Reenaers; Paul Rutgeerts; Curt Tysk; Diana Zelenika; Mark Lathrop; Jurgen Del-Favero; Jean-Pierre Hugot; Martine De Vos; Denis Franchimont; Severine Vermeire; Edouard Louis; Michel Georges

Genome-wide association studies (GWAS) have identified dozens of risk loci for many complex disorders, including Crohns disease. However, common disease-associated SNPs explain at most ∼20% of the genetic variance for Crohns disease. Several factors may account for this unexplained heritability, including rare risk variants not adequately tagged thus far in GWAS. That rare susceptibility variants indeed contribute to variation in multifactorial phenotypes has been demonstrated for colorectal cancer, plasma high-density lipoprotein cholesterol levels, blood pressure, type 1 diabetes, hypertriglyceridemia and, in the case of Crohns disease, for NOD2 (refs. 14,15). Here we describe the use of high-throughput resequencing of DNA pools to search for rare coding variants influencing susceptibility to Crohns disease in 63 GWAS-identified positional candidate genes. We identify low frequency coding variants conferring protection against inflammatory bowel disease in IL23R, but we conclude that rare coding variants in positional candidates do not make a large contribution to inherited predisposition to Crohns disease.


Nature Biotechnology | 2012

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing

Joke Reumers; Peter De Rijk; Hui Zhao; Anthony Liekens; Dominiek Smeets; John Cleary; Peter Van Loo; Maarten J.A. Van Den Bossche; Kirsten Catthoor; Bernard Sabbe; Evelyn Despierre; Ignace Vergote; Brian Hilbush; Diether Lambrechts; Jurgen Del-Favero

Distinguishing single-nucleotide variants (SNVs) from errors in whole-genome sequences remains challenging. Here we describe a set of filters, together with a freely accessible software tool, that selectively reduce error rates and thereby facilitate variant detection in data from two short-read sequencing technologies, Complete Genomics and Illumina. By sequencing the nearly identical genomes from monozygotic twins and considering shared SNVs as true variants and discordant SNVs as errors, we optimized thresholds for 12 individual filters and assessed which of the 1,048 filter combinations were effective in terms of sensitivity and specificity. Cumulative application of all effective filters reduced the error rate by 290-fold, facilitating the identification of genetic differences between monozygotic twins. We also applied an adapted, less stringent set of filters to reliably identify somatic mutations in a highly rearranged tumor and to identify variants in the NA19240 HapMap genome relative to a reference set of SNVs.


Neurology | 2010

Clinical spectrum of early-onset epileptic: encephalopathies associated with STXBP1 mutations

Liesbet Deprez; Sarah Weckhuysen; Philip Holmgren; Arvid Suls; T Van Dyck; Dirk Goossens; Jurgen Del-Favero; A. Jansen; Kristien Verhaert; Lieven Lagae; Albena Jordanova; R. Van Coster; Simone C. Yendle; Samuel F. Berkovic; Ingrid E. Scheffer; Berten Ceulemans; P. De Jonghe

Objectives: Heterozygous mutations in STXBP1, encoding the syntaxin binding protein 1, have recently been identified in Ohtahara syndrome, an epileptic encephalopathy with very early onset. In order to explore the phenotypic spectrum associated with STXBP1 mutations, we analyzed a cohort of patients with unexplained early-onset epileptic encephalopathies. Methods: We collected and clinically characterized 106 patients with early-onset epileptic encephalopathies. Mutation analysis of the STXBP1 gene was done using sequence analysis of the exon and intron–exon boundaries and multiplex amplification quantification to detect copy number variations. Results: We identified 4 truncating mutations and 2 microdeletions partially affecting STXBP1 in 6 of the 106 patients. All mutations are predicted to abolish STXBP1 function and 5 mutations were proven to occur de novo. None of the mutation-carrying patients had Ohtahara syndrome. One patient was diagnosed with West syndrome at disease onset, while the initial phenotype of 5 further patients did not fit into a specific recognized epilepsy syndrome. Three of these patients later evolved to West syndrome. All patients had severe to profound mental retardation, and ataxia or dyskinetic movements were present in 5 patients. Conclusion: This study shows that mutations in STXBP1 are not limited to patients with Ohtahara syndrome, but are also present in 10% (5/49) of patients with an early-onset epileptic encephalopathy that does not fit into either Ohtahara or West syndrome and rarely in typical West syndrome. STXBP1 mutational analysis should be considered in the diagnostic evaluation of this challenging group of patients.


Neurobiology of Aging | 2009

Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS.

Ilse Gijselinck; Kristel Sleegers; Sebastiaan Engelborghs; Wim Robberecht; Jean-Jacques Martin; Rik Vandenberghe; Raphael Sciot; Bart Dermaut; Dirk Goossens; Julie van der Zee; Tim De Pooter; Jurgen Del-Favero; Patrick Santens; Peter Paul De Deyn; Christine Van Broeckhoven; Marc Cruts

The nuclear TAR DNA binding protein (TDP-43) is deposited in ubiquitin-positive inclusions in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two clinicopathologically overlapping neurodegenerative diseases. In this study we excluded mutations and copy number variations in the gene encoding TDP-43 (TARDBP) from an extended series of 173 FTD and 237 ALS patients. Further, we did not identify association of common genetic variants in these patients. Our data implicate that TDP-43 has no primary genetic role in the pathophysiological mechanisms underlying central nervous system neurodegeneration in these diseases.


Neurology | 2010

Mutations in SACS cause atypical and late-onset forms of ARSACS

Jonathan Baets; Tine Deconinck; Katrien Smets; Dirk Goossens; P. Van den Bergh; Karin Dahan; Eric Schmedding; Patrick Santens; Milic Rasic; P. Van Damme; Wim Robberecht; L. De Meirleir; B Michielsens; Jurgen Del-Favero; Albena Jordanova; P. De Jonghe

Background: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a complex neurodegenerative disorder caused by mutations in SACS. The phenotype consists of a childhood-onset triad of cerebellar ataxia, peripheral neuropathy, and pyramidal tract signs. Objective: To provide more insight into the prevalence of SACS mutations and the variability of the associated phenotype. Methods: Mutation screening of SACS by direct sequencing and multiplex amplicon quantification for detection of intragenic copy number variations in a cohort of 85 index patients with phenotypes suggestive for ARSACS. Additional short tandem repeat (STR) marker analysis was performed for haplotype sharing. Results: In 11 families,18 new SACS mutations were found (12.9% of total cohort). Five patients displayed onset ages in adulthood, a feature not known to be associated with ARSACS. The remaining index patients displayed a classic early onset phenotype. Initial phenotypic presentation was atypical in several patients, obscuring the clinical diagnosis. A founder mutation in SACS was identified in 3 Belgian families. In one isolated patient, an intragenic SACS deletion of exons 3–5 was detected. Partial SACS deletions were not previously described. Conclusions: In this study, we enlarge the ARSACS phenotype and the underlying genetic spectrum of SACS mutations. Patients with ARSACS are more common than previously known and risk underdiagnosis due to late onset age and unusual presentation.


Human Mutation | 2009

Simultaneous mutation and copy number variation (CNV) detection by multiplex PCR–based GS‐FLX sequencing

Dirk Goossens; Lotte N. Moens; Eva Nelis; An-Sofie Lenaerts; Andreas Kalbe; Bruno Frey; Guido Kopal; Peter De Rijk; Jurgen Del-Favero

We evaluated multiplex PCR amplification as a front‐end for high‐throughput sequencing, to widen the applicability of massive parallel sequencers for the detailed analysis of complex genomes. Using multiplex PCR reactions, we sequenced the complete coding regions of seven genes implicated in peripheral neuropathies in 40 individuals on a GS‐FLX genome sequencer (Roche). The resulting dataset showed highly specific and uniform amplification. Comparison of the GS‐FLX sequencing data with the dataset generated by Sanger sequencing confirmed the detection of all variants present and proved the sensitivity of the method for mutation detection. In addition, we showed that we could exploit the multiplexed PCR amplicons to determine individual copy number variation (CNV), increasing the spectrum of detected variations to both genetic and genomic variants. We conclude that our straightforward procedure substantially expands the applicability of the massive parallel sequencers for sequencing projects of a moderate number of amplicons (50–500) with typical applications in resequencing exons in positional or functional candidate regions and molecular genetic diagnostics. Hum Mutat 0,1–6, 2008.


Archives of General Psychiatry | 2009

Support for NRG1 as a susceptibility factor for schizophrenia in a northern Swedish isolated population.

Maaike Alaerts; Shana Ceulemans; Diego A. Forero; Lotte N. Moens; Sonia De Zutter; Lien Heyrman; An-Sofie Lenaerts; Karl-Fredrik Norrback; Peter De Rijk; Lars-Göran Nilsson; Dirk Goossens; Rolf Adolfsson; Jurgen Del-Favero

CONTEXTnNeuregulin 1 (NRG1), a growth factor involved in neurodevelopment, myelination, neurotransmitter receptor expression, and synaptic plasticity, first joined the list of candidate genes for schizophrenia when a 7-marker haplotype at the 5 end of the gene (Hap(ICE)) was shown to be associated with the disorder in the Icelandic population. Since then, more genetic and functional evidence has emerged, which supports a role for NRG1 in the development of schizophrenia.nnnOBJECTIVEnTo determine the contribution of NRG1 to susceptibility for schizophrenia in a northern Swedish isolated population.nnnDESIGNnDetailed linkage disequilibrium (LD)-based patient-control association study. This is the first study to type and analyze the 7 Hap(ICE) markers and a set of 32 HapMap tagging single-nucleotide polymorphisms (SNPs) that represents variants with a minor allele frequency of at least 1% and fully characterizes the LD structure of the 5 part of NRG1.nnnSETTINGnOutpatient and inpatient hospitals.nnnPARTICIPANTSnA total of 486 unrelated patients with schizophrenia and 514 unrelated control individuals recruited from a northern Swedish isolated population.nnnMAIN OUTCOME MEASURESnAssociation between markers and disease.nnnRESULTSnAnalysis of the Hap(ICE) markers showed the association of a 7-marker and 2-microsatellite haplotype, different from the haplotypes associated in the Icelandic population and overrepresented in northern Swedish control individuals. Subsequently, a more detailed analysis that included all 37 genotyped SNPs was performed by investigating haplotypic association, dependent and independent of LD block structure. We found significant association with 5 SNPs located in the second intron of NRG1 (.007 </= P </= .04). Also, 2-, 3-, and 4-SNP windows that comprise these SNPs were associated (P < 3 x 10(-4)). One protective haplotype (0% vs 1.8%; P <5 x 10(-5)) and 1 disease risk-causing haplotype (40.4% vs 34.9%, P = .02) were defined.nnnCONCLUSIONnThe NRG1 gene contributes to the susceptibility for schizophrenia in the northern Swedish population.


BMC Genomics | 2010

Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma

Candy Kumps; Nadine Van Roy; Lien Heyrman; Dirk Goossens; Jurgen Del-Favero; Rosa Noguera; Jo Vandesompele; Frank Speleman; Katleen De Preter

BackgroundCancer genomes display characteristic patterns of chromosomal imbalances, often with diagnostic and prognostic relevance. Therefore assays for genome-wide copy number screening and simultaneous detection of copy number alterations in specific chromosomal regions are of increasing importance in the diagnostic work-up of tumors.ResultsWe tested the performance of Multiplex Amplicon Quantification, a newly developed low-cost, closed-tube and high-throughput PCR-based technique for detection of copy number alterations in regions with prognostic relevance for neuroblastoma. Comparison with array CGH and the established Multiplex Ligation-dependent Probe Amplification method on 52 neuroblastoma tumors showed that Multiplex Amplicon Quantification can reliably detect the important genomic aberrations.ConclusionMultiplex Amplicon Quantification is a low-cost and high-throughput PCR-based technique that can reliably detect copy number alterations in regions with prognostic relevance for neuroblastoma.


Toxins | 2014

A qPCR Assay to Detect and Quantify Shiga Toxin-Producing E. coli (STEC) in Cattle and on Farms: A Potential Predictive Tool for STEC Culture-Positive Farms

Karen Verstraete; Els Van Coillie; Hadewig Werbrouck; Stephanie Van Weyenberg; Lieve Herman; Jurgen Del-Favero; Peter De Rijk; Lieven De Zutter; Maria-Adelheid Joris; Marc Heyndrickx; Koen De Reu

Shiga toxin-producing E. coli (STEC), of various serogroups harboring the intimin gene, form a serious threat to human health. They are asymptomatically carried by cattle. In this study, a quantitative real-time PCR (qPCR) method was developed as a molecular method to detect and quantify Shiga toxin genes stx1 and stx2 and the intimin gene eae. Subsequently, 59 fecal samples from six farms were tested using qPCR and a culture method as a reference. Three farms had contaminated animals as demonstrated by the culture method. Culture-positive farms showed moderate significantly higher stx prevalences than culture-negative farms (p = 0.05). This is the first study which showed preliminary results that qPCR can predict STEC farm contamination, with a specificity of 77% and a sensitivity of 83%, as compared with the culture method. Furthermore, the presence or quantity of stx genes in feces was not correlated to the isolation of STEC from the individual animal. Quantitative data thus did not add value to the results. Finally, the detection of both stx and eae genes within the same fecal sample or farm using qPCR was not correlated with the isolation of an eae-harboring STEC strain from the respective sample or farm using the culture method.


Psychiatric Genetics | 2009

Arginine vasopressin receptor gene-based single-nucleotide polymorphism analysis in attention deficit hyperactivity disorder.

Dirk van West; Jurgen Del-Favero; Dirk Deboutte; Christine Van Broeckhoven; Stephan Claes

Department of Molecular Genetics, Applied Molecular Genomics Group, Department of Molecular Genetics, Neurodegenerative Brain Diseases Group, VIB, University of Antwerp (UA), University Center of Child and Adolescent Psychiatry Antwerp (UKJA), Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp and University Psychiatric Center, Campus Leuven, University of Leuven, Leuven, Belgium Correspondence to Dr Dirk van West, MD, MSc, University Center of Child and Adolescent Psychiatry (UKJA), ZNA Middelheim, University of Antwerp, Lindendreef 1, Antwerp B-2020, Belgium Tel: + 32 3 280 49 00; fax: + 32 3 280 49 14; e-mail: [email protected]

Collaboration


Dive into the Jurgen Del-Favero's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Harald Peeters

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dirk Deboutte

Ghent University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge